Click to Hide Hello

Click to Show Hello

Scientific References

Jump to Theralac References | Jump to TruBifido References | Jump to TruFlora References

Theralac Scientific References


Lactobacillus paracasei strain LPC-37

(5 Billion CFU Per Capsule)

Deposited at the American Type Culture Collection (ATCC) as SD5275.

Engelbrektson, A.L., Korzenik, J.R., Sanders, M.E., Clement, B.G., Leyer, G., Klaenhammer, T.R. and Kitts, C.L. (2006). Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol. Ecol. 57:239-250

Paineau, D., Carcano, D., Leyer, G., Darquy, S., Alyanakian, M.A., Simoneau, G., Bergmann, J.F., Brassart, D., Bornet, F. and Ouwehand, A.C. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunology & Medical Microbiology 53(1):107-113

Roessler, A. (nee Klein), Friedrich, U., Vogelsang, H., Bauer, A., Kaatz, M.,Hipler, U.C., Schmidt, I. and Jahreis, G. (2007). The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clinical and Experimental Allergy 38:93-102.

Bifidobacterium lactis strain BL-04

(10 Billion CFU Per Capsule)

Human strain on deposit at the American Type Culture Collection (ATCC) as SD5219

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

B. lactis is on the EU Safety List for Human consumption.

Borriello, S.P., Hammes, W.P., Holzapfel, W., Marteau, J., Schrezenmeir, J., Vaara, M. and Valtonen, V. (2003). Safety of Probiotics That Contain Lactobacilli or Bifidobacteria. Clinical Infect. Disease 36:775-780.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo, M.E.T. and Macfarlane, G.T. (2005). Microbiological effects of consuming a symbiotic containing Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clinical Infect. Diseases. 40:28-37.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P., Rizello, F., Caramelli, E., Matteuzzi, D. and Campieri, M. (2003). Immunomodulatory effects of probiotic bacteria DNA:IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology 38:165-172.

Bifidobacterium lactis strain Bi-07

(10 Billion CFU Per Capsule)

Complimentary human strain synergistic with BL-34 on deposit at the American Type Culture Collection (ATCC) as SD5220.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun. 65:4165-4172.

Ruiz-Palacios, G.F., Guerrero, M., Hilty, M., Dohnalek, P., Newton, P., Calva, J.J., Tostigan, T., Tuz, F. and Arteaga, M.L. (1999). Feeding of a probiotic for the prevention of community acquired diarrhea in young Mexican children. Pediatr. Res. 39(2):104 (abstr).

Provisional Patent Application. Ser. No. 60/848,662 filed on 2 October 2006.

Lactobacillus rhamnosus strain LR-32

(2 Billion CFU Per Capsule)

Deposited at the American Type Culture Collection (ATCC) as SD5217.

Collins, M.D., Phillips, B.A. and Zanoni, P. (1989). Deoxy-ribonucleic acid homology studies of Lactobacillus casei, Lactobacillus paracasei sp. nov. subsp. Paracasei and subsp. Tolerans and Lactobacillus rhamnosus sp. nov. comb. nov. International Journal of Systemic Bacteriology 39:105-108.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology. 13(2):236-243.

Foligne, B., Zoumpopoulou, G., Dewulf, J., Ben Younes, A., Chareyre, F., Sirard, J.-C., Pot, B. and Grangette, C. (2007). A Key Role of Dendritic Cells in Probiotic Functionality. PloS ONE 2(3):e313. doi:10.137l/journal.pone.0000313.

List of taxonomic units proposed for QPS status http://www.efsa.europa.eu/en/efsajournal/doc/587.pdf.

Lactobacillus acidophilus strain LA-1 (NCFM)

(10 Billion CFU Per Capsule)

Note: Some references refer to this strain as LA-5. Bifidobacterium TB-12 is also included in some of the references cited for LA-1.

Human strain on deposit at the American Type Culture Collection (ATCC) as SD5221.

Wagner R., Warner, T.,Robert, L., Farmer, J. and Balish, E. (1997). Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect. Immun. 65:3345-3351.

Sui, J., Leighton, S., Busta, F. and Brady L. (2002). 16s ribosomal DNA analysis of the fecal lactobacilli composition on human subjects consuming a probiotic strain Lactobacillus acidophilus NCFM. J. Appl. Microbiol. 93:907-912.

Varcoe, J., Zook, C., Sui, J., Leighton, S., Busta, F. and Brady L. (2002) Variable response to exogenous Lactobacillus acidophilus NCFM consumed in different vehicles. J. Appl. Microbiol. 93:900-906.

Greene, J.D. and Klaenhammer, T.R. (1994). Factors involved in adherence of lactobacilli to human Caco-2 cells. Appl. Environ. Microbiol. 60:4487-4494.

Kleeman, E.G. and Klaenhammer, T.R. (1982). Adherence of Lactobacillus species to human fetal intestinal cells. J. Dairy Sci. 65:2063-2069.

Gilliland, S.E., and Speck, M.L. (1977). Deconjugation of Bile Acids by Intestional Lactobacilli. Appl. Environ. Microbiol., 33(1):15-18.

Goldin, B.R., Swenson, L., Dwyer, J., Sexton, M. and Gorbach, S.L. (1980). Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J. Natl. Cancer Inst. 64(2):255-261.

Varcoe, J.J., Krejcarek, G., Busta, F. and Brady, L. (2003). Prophylactic feeding of Lactobacillus acidophilus NCFM to mice attenuates overt colonic hyperplasia. J. Food Prot. 66(3):457-465.

Kim, H.S. and Gilliland, S.E. (1983). Lactobacillus acidophilus as a dietary adjunct for milk to aid lactose digestion in humans. J. Dairy Science. 66(5):959-966.

Dunn, S.R., Simenhoff, M.L., Ahmed, K.E., Gaughan, W.J., Eltayeb, B.O., Fitzpatrick, M.-E.D., Emery, S.M., Ayres, J.W. and Holt, K.E. (1998). Effect of oral administration of freeze-dried Lactobacillus acidophilus on small bowel bacterial overgrowth in patients with end stage kidney disease: reducing uremic toxins and improving nutrition. Int. Dairy J. 8:545-553.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of probiotic bacteria on candidasis in immunodeficient mice. Infect. Immun. 65(10):4165-4172.

Tejada-Simon, M.V., Lee, J.H., Ustunol, Z. and Pestka, J.J. (1999). Injestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin. A response to cholera in mice. J. Dairy Sci. 82:649-660.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Hilty, M. and Balish, E. (2000). Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J. Food Prot. 63(5):638-644.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Sanders, M.E., Walker, D.C., Walker, K.M., Aoyama, K. and Klaenhammer, T.R. (1996). Performance of commercial cultures in fluid milk applications. J. Dairy Sci. 79:943-955. (Strain LH1=NCFM).

TruBifido Scientific References


Bifidobacterium lactis strain BL-04

(21 Billion CFU Per Capsule)

Human strain on deposit at the American Type Culture Collection (ATCC) as SD5219

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

B. lactis is on the EU Safety List for Human consumption.

Borriello, S.P., Hammes, W.P., Holzapfel, W., Marteau, J., Schrezenmeir, J., Vaara, M. and Valtonen, V. (2003). Safety of Probiotics That Contain Lactobacilli or Bifidobacteria. Clinical Infect. Disease 36:775-780.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo, M.E.T. and Macfarlane, G.T. (2005). Microbiological effects of consuming a symbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clinical Infect. Diseases. 40:28-37.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P., Rizello, F., Caramelli, E., Matteuzzi, D. and Campieri, M. (2003). Immunomodulatory effects of probiotic bacteria DNA:IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology 38:165-172.

Bifidobacterium lactis strain Bi-07

(3 Billion CFU Per Capsule)

Complimentary human strain synergistic with BL-34 on deposit at the American Type Culture Collection (ATCC) as SD5220.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun. 65:4165-4172.

Ruiz-Palacios, G.F., Guerrero, M., Hilty, M., Dohnalek, P., Newton, P., Calva, J.J., Tostigan, T., Tuz, F. and Arteaga, M.L. (1999). Feeding of a probiotic for the prevention of community acquired diarrhea in young Mexican children. Pediatr. Res. 39(2):104 (abstr).

Provisional Patent Application. Ser. No. 60/848,662 filed on 2 October 2006.

Bifidobacterium lactis strain HN019

(2 Billion CFU Per Capsule)

Coming Soon.

Bifidobacterium breve strain BB-03

(2 Billion CFU Per Capsule)

Coming Soon.

Bifidobacterium bifidum strain BB-06

(2 Billion CFU Per Capsule)

Coming Soon.

TruFlora Scientific References


Lactobacillus Plantarum strain LP-115

(10 Billion CFU Per Capsule)

Deposited at the American Type Culture Collection (ATCC) as SD5209.

Mogensen, G., Salminen, S., O’Brien, J., Ouwehand, A.C., Holzapfel, W., Shortt, C., Fonden, R., Miller, G.D., Donohue, D., Playne, M., Crittenden, R., Salvadori, B. & Zinc, R. (2002). Inventory of microorganisms with a documented history of safe use in food. Bulletin of the International Dairy Federation. 377:10-19.

Daniel, C., Poiret, S., Goudercourt, D., Dennin, V., Leyer, G. & Pot, B. (2006). Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model. Applied and Environmental Microbiology. 72(9):5799-5805.

Collado, M.C., Meriluoto, J. & Salminen, S. (2007). Adhesion and aggregation properties of probiotic and pathogenic strains. Eur Food Res Technol. DOI 10.1007/s00217-007-0632-x.

Collado, M.C, Meriluoto, J. & Salminen, S. (2007). Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Letters in Applied Microbiology. oi:10.1111/j.1472-765X.2007.02212.x.

Turroni, S., Vitali, B., Bendazzoli, C., Candela, M., Gotti, R., Federci, F., Pirovano, F. & Brigidi, P. (2007). Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. Journal of Applied Microbiology (OnlineEarly Articles). Doi:10.1111/j.1365-2672.2007.03388.x.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Merceneir, A. & Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13(2):236-243.

Lactobacillus salivarius strain LS-33

(3 Billion CFU Per Capsule)

Deposited at the American Type Culture Collection (ATCC) as SD5208.

Mogensen, G., Salminen, S., O’Brien, J., Ouwehand, A.C., Holzapfel, W., Shortt, C., Fonden, R., Miller, G.D., Donohue, D., Playne, M., Crittenden, R., Salvadori, B. & Zinc, R. (2002). Inventory of microorganisms with a documented history of safe use in food. Bulletin of the International Dairy Federation. 377:10-19.

Daniel, C., Poiret, S., Goudercourt, D., Dennin, V., Leyer, G. & Pot, B. (2006). Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model. Applied and Environmental Microbiology. 72(9):5799-5805.

Collado, M.C., Meriluoto, J. & Salminen, S. (2007). Adhesion and aggregation properties of probiotic and pathogenic strains. Eur Food Res Technol. DOI 10.1007/s00217-007-0632-x.

Collado, M.C, Meriluoto, J. & Salminen, S. (2007). Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Letters in Applied Microbiology. Doi:10.1111/j.1472-765X.2007.02212.x.

Fogligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. & Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology. 13(2):236-243.

Foligne, B., Zoumpopoulou, G., Dewulf, J., Ben Younes, A., Chareyre, F., et al. (2007). A Key Role of Dendritic Cells in Probiotic Functionality. PloS ONE 2(3):e313.doi:10.1371/journal.pone.0000313.

Bacillus coagulans strain IS-2

(2 Billion CFU Per Capsule)

Doron, Shira I., MD, . Hibberd, Patricia L, MD, PhD, and . Gorbach, Sherwood L, MD. “Probiotics for Prevention of Antibiotic-associated Diarrhea”.  Journal of Clinical Gastroenterology 42.Supp.2 (July 2008): S58-63.

Sudha, Ratna M., Sunita, M., Sekhar, Babu M., “Safety Studies of Bacillus Coagulans  Unique IS-2 in Rats: Morphological, Biochemical and Clinical Evaluations”. International Journal of Probiotics and Prebiotics Vol. 6.No. 1, (2011): 43-48.

Devi, Sucharitha, Yasoda P. Devi, and Siva M. Prakash.” Effect of Lactobacillus Supplementation on Immune Status of Malnourished Pre-school Children”. Indian Journal of Pediatrics. Vol. 66 (1999): 663-68.

Sudha, Ratna M., Prashant Chauhan, Kalpana Dixit, Sekhar Babu, and Kaiser Jamil. "Probiotics as Complementary Therapy for Hypocholesteremia." Biology and Medicine. Vol. 1.Rev. 4 (2009): 1-13.

Sudha, Ratna. M.,and  Bhonagiri, Shivaram. “Efficacy of Bacillus Coagulans Strain Unique IS-2 in the Treatment of Patients with Acute Diarrhea”. International Journal of Probiotics and Prebiotics. Vol. 7, No. 1 (2012).

Sudha, Ratna M., Radkar, Neelam, and Mayrya, Asin. “Effect of Supplementation of Probiotic Bacillus Coagulans Unique IS-2 on Hypercholesterolemia Subjects: A Clinical Study”. International Journal of Probiotics and Prebiotics. Vol. 6. No. 2 (2011).

Sudha, Ratna M., Chauhan, P, Dixit, K.,Babu, S., and Jamil, K. “Molecular Typing and Probiotic Attributes of a New Strain of Bacillus coagulans- Unique IS-2: a Potential Biotherapeutic Agent”. Genetic Engineering and Biotechnology Journal, 7 (2010) Research Article 1-16.

Sudha, Ratna M., Chauhan, P., Dixit, K., Babu, S., and Jamil, K. “Probiotics as Complementary Therapy for Hypercholesterolemia”. Biology and Medicine, Vol.1 (4):Rev4 (2009).